ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Efficacy and Safety of Emicizumab Prophylaxis in Severe Haemophilia A without Inhibitors: A Report from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO)

C. Wall1, H. Xiang2, B.P Palmer2, E. Chalmers3, P. Chowdary4, P.W Collins5, S. Fletcher6, D.P Hart7, G.W Hall8, R. Liesner9, S. Shapiro6, D. Stevensen10, K. Talks11, C.RM Hay1, United Kingdom Haemophilia Centre Doctors' Organisation

1Manchester Royal Infirmary, Manchester, United Kingdom, 2UK National Haemophilia Database, Manchester, United Kingdom, 3Royal Hospital for Sick Children, Glasgow, United Kingdom, 4Royal Free Hospital, London, United Kingdom, 5University Hospital of Wales, Cardiff, United Kingdom, 6Churchill Hospital, Oxford, United Kingdom, 7Royal London Hospital, London, United Kingdom, 8Oxford Children's Hospital, Oxford, United Kingdom, 9Great Ormond Street Hospital, London, United Kingdom, 10Kent and Canterbury Hospital, Canterbury, United Kingdom, 11Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

Abstract Number: PB0511

Meeting: ISTH 2021 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: Real-world reports of outcomes of emicizumab prophylaxis in severe haemophilia A (SHA) without inhibitors are limited.

Aims: To evaluate the efficacy and safety of emicizumab across the UK

Methods: This prospective, observational study used registry and Haemtrack (HT) patient reported outcome data from patients prescribed emicizumab between 01/08/2019-30/09/2020. Short-term efficacy (ABR, AJBR and bleed-free proportion) were determined and compared with prior FVIII prophylaxis (within-person analysis) in patients with ≥ 6 months HT data before and after switching. Adverse events (AE) were adjudicated by the Co-Morbidities Working Party.

Results: Emicizumab was prescribed to 378 subjects, median (IQR) age 36.0 (31.0; 45.5), including 83 <18 years – 15 were previously untreated and 18 minimally treated patients. Within-person comparison in 179 with ≥ 6 months pre/post switching HT data (including 40 using rFVIIIFc prophylaxis), demonstrated significant reduction in bleeding rates with emicizumab (table). The overall bleed-free proportion increased from 37% to 75% in the 36 weeks before and after switching (P<0.001).  A sub-analysis of the 44/179 who reported bleeding after switching showed a higher median (IQR) pre-switch ABR of 5.21 (2.20; 16.0) reducing to 1.90 (1.52; 3.67) post; a change of -3.22 (-10.0; -0.36), (p< 0.001).  AEs, reported in 9/378 (2.4%), occurred predominantly during loading and included: grade 1-2 cutaneous reactions in three, severe headaches in three (resulting in drug cessation in one) and poor efficacy, unrelated to anti-drug antibodies, in one person who reverted to rFVIIIFc prophylaxis.  Recurrence of a FVIII inhibitor (Bethesda negative for ~ 4 years) was reported after 6 months emicizumab therapy without factor VIII exposure. One death, unrelated to emicizumab, was reported. No thrombotic or microangiopathic events occurred.  

Conclusions:

Follow-up (weeks) Med. (IQR) age
(years)
Med. (IQR) ABR Med. (IQR) AJBR Bleed-free
n (%)†
Med. (IQR) change in ABR
All products pre-switch n=179* 103 (94;109) 30 (14.0; 46.0) 2.46 (0.5; 7.1) 1.37 (0.0; 4.7) 67 (37)

-2.15 (-6.36; 0.08)
P <0.00
Emicizumab post-switch 36.0 (30.0; 44.0) 0.0 (0.0;0.0) 0.0 (0.0;0.0) 135 (75)
P <0.001
rFVIII pre-switch
n=134*
104 (94; 109) 31 (13; 46) 2.6 (0.5; 8.1) 1.6 (0.0; 4.8) 49 (37) -2.48 (-6.69; -0.04)
P <0.001
Emicizumab post-switch 35 (30; 42) 0.0 (0.0;0.0) 0.0 (0.0;0.0) 103 (77)
P <0.001
rFVIIIFc pre-switch
n=40*
100 (94.8; 107) 30.5
(18.5; 47.8)
2.19 (0.6; 5.4) 1.06 (0.0: 3.4) 16 (40) -1.38 (-3.83; 0.00)
P <0.001
Emicizumab post-switch 37.8 (33; 44.5) 0.0 (0.0; 0.0) 0.0 (0.0;0.0) 28 (70)
P <0.001
* n=5 with mixed rFVIII and rFVIIIFc during the study period were not included in the sub-analysis by factor replacement type
† follow-up periods pre and post matched to median 36 weeks for comparison of bleed-free rates

Within-person analysis of emicizumab with prior prophylaxis
Significant reductions in Haemtrack reported bleeding events were observed after changing to emicizumab prophylaxis in UK clinical practice. The safety profile appears acceptable but ongoing pharmacovigilance is required to determine long-term outcomes.

To cite this abstract in AMA style:

Wall C, Xiang H, P Palmer B, Chalmers E, Chowdary P, W Collins P, Fletcher S, P Hart D, W Hall G, Liesner R, Shapiro S, Stevensen D, Talks K, RM Hay C, United Kingdom Haemophilia Centre Doctors' Organisation . Efficacy and Safety of Emicizumab Prophylaxis in Severe Haemophilia A without Inhibitors: A Report from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/efficacy-and-safety-of-emicizumab-prophylaxis-in-severe-haemophilia-a-without-inhibitors-a-report-from-the-uk-haemophilia-centre-doctors-organisation-ukhcdo/. Accessed July 1, 2022.

« Back to ISTH 2021 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/efficacy-and-safety-of-emicizumab-prophylaxis-in-severe-haemophilia-a-without-inhibitors-a-report-from-the-uk-haemophilia-centre-doctors-organisation-ukhcdo/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley